WASHINGTON (CN) - The Food and Drug Administration plans to reclassify the external pacemaker, so manufacturers have to follow "special controls" in a guidance document instead notifying the FDA when the manufacturer will be marketing the product.
An external pacemaker is used as a temporary substitute for the heart's intrinsic pacing system until a permanent pacemaker can be implanted, or to control irregular heartbeats in patients following cardiac surgery or a heart attack. It produces a periodic electrical pulse to make the heart pump blood.
In 2009, the FDA requested information on the devices, and it received reclassification petitions from three device manufacturers. The manufacturers stated that safety and effectiveness of these devices may be assured by design and maintenance (special controls), consideration of risks involved with the device, and an independent verification that appropriate standard operating procedures are in place and being followed.
Click the document icon for this regulation and others.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
Additional Reads
-
Alaska, Hawaiian Airlines April 17, 2024 -
-
Contributor-Test-Post-2024-04-12 April 12, 2024 -
